VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Concepcion on Bladder Cancer Treatment and Costs

Raoul S. Concepcion, MD
Published: Thursday, Jun 14, 2012

Raoul S. Concepcion, MD, editor-in-chief, Urologists in Cancer Care, Director of Clinical Research, Urologic Surgeon, Urology Associates, PC, Nashville, TN, discusses the costs and novel treatments on the horizon for patients with bladder cancer.

Concepcion believes that bladder cancer comes in two forms: non–muscle invasive and invasive. He adds that non-invasive bladder cancer is one of the most expensive forms of cancer because of the costs associated with the extensive monitoring and follow-up that is needed to detect recurrence or invasion into the muscle.

In order to help ease costs and to ensure better outcomes, companies are currently investigating biological markers for non-invasive bladder cancer that could help predict the tumors that are at high-risk of progressing or recurring.

Additionally, for invasive bladder cancer the company Dendreon is examining the HER2/neu targeted immunotherapy DN24-02. This therapy is currently in a phase II adjuvant trial for patients with HER2-positive urothelial carcinoma following surgical resection.

Raoul S. Concepcion, MD, editor-in-chief, Urologists in Cancer Care, Director of Clinical Research, Urologic Surgeon, Urology Associates, PC, Nashville, TN, discusses the costs and novel treatments on the horizon for patients with bladder cancer.

Concepcion believes that bladder cancer comes in two forms: non–muscle invasive and invasive. He adds that non-invasive bladder cancer is one of the most expensive forms of cancer because of the costs associated with the extensive monitoring and follow-up that is needed to detect recurrence or invasion into the muscle.

In order to help ease costs and to ensure better outcomes, companies are currently investigating biological markers for non-invasive bladder cancer that could help predict the tumors that are at high-risk of progressing or recurring.

Additionally, for invasive bladder cancer the company Dendreon is examining the HER2/neu targeted immunotherapy DN24-02. This therapy is currently in a phase II adjuvant trial for patients with HER2-positive urothelial carcinoma following surgical resection.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x